MD
MDAI.O
—
NASDAQ
Healthcare Equipment
Spectral AI Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
50,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-43,8 %
ROE
132,2 %
Net margin
-38,5 %
Debt / equity
-1,47
Beta
—
52w range
—
Volume
562
Day range
—
Prev close
$2,31
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Spectral AI Inc develops and commercializes AI-powered medical imaging solutions for diagnostic and therapeutic applications in healthcare.
Business. Spectral AI Inc (MDAI.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupHealthcare Equipment
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target4,67
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
4,67
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
132,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MDAI.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Spectral AI Inc (MDAI.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupHealthcare Equipment
AI synthesis
GENERATEDSpectral AI operates with a cash balance of $15.4 million against $27.1 million in total liabilities, resulting in a negative equity position of $5.7 million. The company's liquidity position is rated as low, with a current ratio of 0.94 and negative free cash flow of $7.5 million in the latest period. The enterprise value to revenue multiple of 3.09 suggests market optimism despite the company's negative EBITDA of $7.57 million.
The company's financial performance shows significant underperformance relative to industry norms. With a return on equity of 1.32% and a negative return on assets of -0.35%, Spectral AI lags behind the typical performance metrics for advanced medical equipment firms. The operating margin of -43.8% (calculated from $8.6 million operating loss on $19.7 million revenue) indicates structural cost challenges.
Geographically, the company's revenue concentration data is not available in the current dataset. Segmental breakdowns also remain undisclosed, suggesting a lack of transparency in operational diversification. This opacity limits the ability to assess risk distribution across product lines or geographic markets.
Looking ahead, the company faces a challenging growth trajectory. With no revenue growth data available and a current operating loss, the outlook for near-term profitability remains uncertain. Analysts have assigned a mean price target of $4.67, implying a 124% upside from the current market price of $2.13, but the absence of disclosed revenue growth metrics makes this target speculative.
Risk factors include the company's negative equity position and operating cash flow deficit. The dilution risk is currently rated as low, with no immediate filing-based flags detected. However, the company's capital structure shows a debt-to-equity ratio of -1.47, indicating that liabilities exceed equity by a significant margin.
Recent filings and transcripts do not show any material events that would significantly alter the company's risk profile. The absence of recent strategic announcements or product launches suggests a period of operational stability but also limited visibility into future growth drivers.
Key takeaways
- The company maintains a cash buffer of $15.4 million but faces a liquidity risk due to $27.1 million in liabilities.
- Spectral AI's financial performance lags industry norms with a negative return on assets of -0.35%.
- Analysts project a mean price target of $4.67, implying a 124% upside from the current market price.
- The company's capital structure shows a debt-to-equity ratio of -1.47, indicating significant leverage.
- No immediate dilution or liquidity flags were detected in recent filings.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,60
Market cap
$67.8M
Enterprise valueⓘ
$60.8M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$5.7M
Net cashⓘ
$7.0M
Current ratioⓘ
0.9
Debt / equityⓘ
-1.5
ROAⓘ
-35.4%
ROEⓘ
1.3%
Cash conversionⓘ
131.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Partners1
Polynovo LtdPNV.AXPartner95%Source ↗
Supply chain
Vendors → MDAI ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs MDAI · multiples and returns
VE
VEEV—
Veeva Systems Inc
$158,86
25,9B USDP/E
157,9x
— vs self
Div yield
—
— vs self
ROE
3,3 %
-128,9 vs self
QD
QDEL—
QuidelOrtho Corporation
$17,71
1,2B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-58,9 %
-191,1 vs self
EV
EVH—
Evolent Health, Inc.
$3,14
351,4M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-134,8 %
-267,0 vs self
OM
OMCL—
OMNICELL, INC.
$46,82
—P/E
—
— vs self
Div yield
—
— vs self
ROE
1,7 %
-130,5 vs self
TB
TBRG—
Trubridge Inc
$26,24
393,6M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-1,0 %
-133,2 vs self
LF
LFMD—
Lifemd Inc
$3,73
177,5M USDP/E
13,6x
— vs self
Div yield
—
— vs self
ROE
62,0 %
-70,2 vs self
SL
SLP—
SIMULATIONS PLUS, INC.
$18,31
370,5M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-46,6 %
-178,8 vs self
SO
SOPH—
Sophia Genetics SA
$5,80
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,48
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,48 |
| Revenue | —no estimate | —no estimate | 18,9M USD |
| Operating income | —no estimate | —no estimate | -14,7M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy1
Buy1
Hold0
Sell0
Strong sell0
12-month price target$4,67 · Median $5,00
Low $3,00High $6,00
Operating income · consensus-14,7M USD
EPS surprise
+40,0 %
reported vs consensus · beat
Revenue surprise
+4,2 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,00
Mean$4,67
Median$5,00
High$6,00
Spot$1,60
+191.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-43,8 %Above median
Net Margin-38,5 %Above median
ROE132,2 %Best in class
D/E-1,47Best in class
Cash Conv1,31Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- Spectral AI Inc Market data — financials · 2026-05-28
- Spectral AI Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $05 insiders · last 365d
- Director · Common StockOther 15 000 @ $2,12$32K · 2026-05-29
- Director · Common StockOther 2 500 @ $2,36$6K · 2026-05-28
- Director · Common StockOther 32 233 @ $2,61$84K · 2026-05-26
- Director · Common StockOther 8 818 @ $2,40$21K · 2026-05-18
- Director · Common StockOther 1 887 @ $2,12$4K · 2026-05-15
- Director · Common StockOther 25 000 @ $2,16$54K · 2026-05-15
- Director · Common StockOther 5 882 @ $2,33$14K · 2026-05-15
- Chief Executive Officer · Common StockOther 100 000 · 2026-04-24
- Director · Common StockOther 25 000 · 2026-04-24
- Director · Common StockOther 100 000 · 2026-04-24
- Director · Common StockOther 29 850 · 2026-04-24
- Director · Common StockOther 25 000 · 2026-04-24
- Director · Common StockOther 7 619 @ $1,58$12K · 2026-03-27
- Chief Executive Officer · Common StockOther 16 750 @ $1,52$25K · 2026-03-27
Short positioning
2.6Mshares short+13.0% vs prior
12.66days to cover
47.9%short of daily vol
3.2Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MDAI.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -7.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -33.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 231.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 65.9%Derived (calculated)
- Net margin (FY 2025-12-31): -38.5%Derived (calculated)
- Gross margin (FY 2025-12-31): 45.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 132.2%Derived (calculated)
- Return on assets (FY 2025-12-31): -35.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.94xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): -4.74xDerived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -32.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -34.2%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 196.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 50.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 77.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 40.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -30.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 21.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 65.9%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Total operating expenses (annual): USD 17.53MSEC XBRL filing
- Pre-tax income (annual): USD -7.56MSEC XBRL filing
- Cost of revenue (annual): USD 10.72MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-29 00:00 UTCINSIDER7 insider transactions — 2026-05 · net buy $215k
2026-05-29INSIDERDiMaio John Michael transacted 15.0k sh — Director ~$32k
2026-05-28INSIDERDiMaio John Michael transacted 2.5k sh — Director ~$6k
2026-05-26INSIDERDiMaio John Michael transacted 32.2k sh — Director ~$84k
2026-05-18INSIDERCotton Richard John transacted 8.8k sh — Director ~$21k
2026-05-15INSIDERDiMaio John Michael transacted 1.9k sh — Director ~$4k
2026-05-15INSIDERDiMaio John Michael transacted 25.0k sh — Director ~$54k
2026-05-15INSIDERCotton Richard John transacted 5.9k sh — Director ~$14k
2026-04-24 00:00 UTCINSIDER5 insider transactions — 2026-04
2026-04-24INSIDERCapone Vincent S. transacted 100.0k sh — Chief Executive Officer
2026-04-24INSIDERSadagopan Deepak transacted 25.0k sh — Director
2026-04-24INSIDERDiMaio John Michael transacted 100.0k sh — Director
2026-04-24INSIDERCotton Richard John transacted 29.9k sh — Director
2026-04-24INSIDERSnyder Marion Ann transacted 25.0k sh — Director
2026-03-27 00:00 UTCINSIDER2 insider transactions — 2026-03
2026-03-27INSIDERDiMaio John Michael transacted 7.6k sh — Director ~$12k
2026-03-27INSIDERCapone Vincent S. transacted 16.8k sh — Chief Executive Officer ~$25k
2025-06-10 00:00 UTCINSIDER3 insider transactions — 2025-06
2025-04-30 00:00 UTCINSIDER3 insider transactions — 2025-04
2024-05-15 00:00 UTCINSIDER7 insider transactions — 2024-05 · net buy $196k
2024-01-19 00:00 UTCINSIDER2 insider transactions — 2024-01
2023-11-20 00:00 UTCINSIDER4 insider transactions — 2023-11
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage